Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma

Lancet. 1984 Aug 25;2(8400):427-31. doi: 10.1016/s0140-6736(84)92907-6.

Abstract

Eight patients with relapsed B-cell non-Hodgkin's lymphoma were treated with intensive chemoradiotherapy and reconstituted with autologous bone marrow rendered free of tumour cells by the B-cell-specific monoclonal antibody anti-B1 and complement. Before the autologous marrow transplantation patients were induced with chemotherapy, radiotherapy, or both, into a minimum disease state with less than 5% bone-marrow involvement with tumour. All patients treated achieved a complete clinical response and had stable haematological engraftment by 8 weeks. No significant acute or chronic toxic effects have occurred. B cells could be detected by 2 months after transplantation and normal immunoglobulin levels were achieved by 6 months. Six of eight patients are disease free in unmaintained remission more than 20, 19, 10, 8, 5, and 3 months after transplantation.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antibodies, Monoclonal / administration & dosage*
  • B-Lymphocytes / immunology*
  • Bone Marrow Transplantation*
  • Combined Modality Therapy
  • Complement System Proteins*
  • Female
  • Humans
  • Lymphoma / drug therapy
  • Lymphoma / radiotherapy
  • Lymphoma / therapy*
  • Male
  • Middle Aged
  • Recurrence
  • Transplantation, Autologous

Substances

  • Antibodies, Monoclonal
  • Complement System Proteins